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New Year Message from the President
Dr Raymond SK LO
President 
The Federation of Medical Societies of Hong Kong
Dr Raymond SK LO
Time flies by swiftly, and we are stepping into a bright new year. First of all, on behalf of the Federation of Medical 
Societies of Hong Kong, may I wish you a healthy and prosperous year of 2014.
The past year has indeed been another rich and productive year for the Federation. Our fraternity has remained strong 
with a total of 133 member societies. The Presidents’ and Editors’ Dinner held in September was a success. Our annual 
event of Presidents’ Cup of Soccer Five & Basketball Tournament was blessed with a record number of teams enrolled. 
The New Year’s Eve Dinner of 2013 with the theme of “Federation Cruise” proved to be another memorable evening, 
with revenue going towards the theatresports programme of our charity project for bereaved children. 
As the umbrella organisation of medical, dental, nursing and allied health professional societies of Hong Kong, we 
strive for the betterment for our health professions. From the educational perspective, our Annual Scientific Meeting 
last year on the timely issue of “Obesity-related disorders: an emerging epidemic” was very well received. The 
number of seminars and certificate courses held last year was another record high. We welcome further initiatives with 
members and various partners in delivering quality academic activities for our members and professions in the years 
to come.
It is also the mission of our Federation to promote the health and well-being of our population at large. Important 
health messages from our population survey on childhood obesity were widely promulgated through the media last 
summer. Health talks to the public included a wide range of topics on infectious diseases, cancer care and nutrition, 
dental implants etc. Our weekly radio programme at RTHK and health festivals remained popular. More health 
education for our public is in demand, and the Federation and Foundation will devote increasing strengths and efforts. 
For the advocacy role in safeguarding the health of our public, the Federation has nominated representatives to 
government committees and Legislative Council meetings on issues such as cosmetic and beauty services, and 
regulation of clinical procedures in ambulatory setting. Various medical and health issues will need our feedback and 
advice, and we shall be actively seeking your views.    
  
Our Federation is here to serve, and the goal of continuing growth and development for the common good of our 
professions will very much rely on your participation. Thank you for your continuing support to the Federation, and 
with the concerted efforts we are confident of taking our activities to new heights in 2014. We look forward to working 
alongside with you in the near future.
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Editorial
Editorial 
Urological problems are common encounters in our clinical practice. 
Although in the past it has largely been considered to be a minor 
subspecialty in our current medical profession practice. Many of these 
nonmalignant urological conditions do not kill. However they still 
affect one’s quality of life significantly. When patients suffering from 
urological diseases like urinary stones, Lower urinary tract symptoms 
LUTS (formerly known as prostatism) or even erectile dysfunction, 
they often seek advice from their family doctors first. In fact many of 
these cases could be first well managed by family physicians before 
they are referred to urologists for specialised care or surgery. Another 
important aspect of urology problems faced by our family physicians 
is the management of incidental findings during health checks. Often 
patients have urine or ultrasound tests done as part of their health 
check package. They may discover microscopic haematuria or small 
kidney masses and ask for opinions, etc. It would be important for us 
to understand the clinical significance and principle of management 
of these common problems before we start counselling them with 
confidence. 
In this issue of the Medical Diary we have asked some of our urologist 
colleagues to update our readers on the concept and principle of 
management of these common encounters in clinical practice. We hope 
this could provide some in depth knowledge for our family physicians, 
or specialists of other medical specialties to better manage, provide 
counselling and timely referrals of these patients for further care. 
MBBS(HK), FRCS(Ed.), FCSHK, Dip. Urol.(London), 
FHKAM(Surgery)
Chief and Consultant, Division of Urology, Department of Surgery,
University of Hong Kong, Queen Mary Hospital
Editor
www.apro.com.hk
Dr Ming-kwong YIU
Dr Ming-kwong YIU
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Dr Ming-kwong YIUDr James HL TSU
Diagnostic Evaluation of Lower Urinary 
Tract Symptoms in Men
Dr James HL TSU
Dr Ming-kwong YIU
MBBS, FRCS(Urol)
MBBS(HK), FRCS(Ed.), FCSHK, Dip. Urol.(London), FHKAM(Surgery)
Associate consultant, Division of Urology, Department of Surgery, 
University of Hong Kong Queen Mary Hospital
Chief and Consultant, Division of Urology, Department of Surgery,
University of Hong Kong, Queen Mary Hospital
This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical 
Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded 1 CME credit under the programme 
upon returning the completed answer sheet to the Federation Secretariat on or before 31 January 2014.
Introduction 
The histological  diagnosis  of  benign prostatic 
hyperplasia (BPH), with the secondary effect of benign 
prostate enlargement, and its associated complications 
including bladder outlet obstruction (BOO) and lower 
urinary tract symptoms (LUTS), are some of the most 
prevalent disorders currently affecting men. However, 
during the last decade the causal link between the 
prostate and the pathogenesis of LUTS has come into 
question and it is now believed many factors, other than 
the prostate can contribute to the LUTS seen in elderly 
men.1 The correct management of LUTS hinges on the 
evidence-based evaluation and investigation of LUTS. 
Herein we describe an updated diagnostic evaluation 
approach to adult men presenting with LUTS, based on 
published guidelines from major urological bodies.2-4
Nomenclature 
The term LUTS was introduced in 1994 to escape 
the ‘prostate-centric’ approach of doctors to this 
constellation of voiding symptoms seen in men, 
which led to many men having unnecessary prostate 
surgeries when their symptoms had other causes.5 The 
old term ‘prostatism’ was conceptually wrong as it 
had become clear that a significant amount of patients 
with ‘prostatism’ were in fact suffering from conditions 
unrelated to their prostate glands. LUTS is divided into 
1) storage symptoms which are experienced during 
the storage phase of the bladder and include daytime 
frequency, nocturia and urgency, and 2) voiding 
symptoms which are experienced during the voiding 
phase. The latter include a weak stream, hesitancy and 
the need for straining during voiding.6 LUTS may be 
due to structural or functional abnormalities in one 
or more of the parts of the lower urinary tract which 
comprises the bladder, bladder neck, prostate, distal 
sphincter mechanism and urethra. It must also be 
remembered that LUTS may result from abnormalities 
of the peripheral and/or central nervous system(s) 
which provide neural control to the lower urinary 
tract. LUTS may also be secondary to cardiovascular, 
respiratory or renal dysfunction or disease.4 To this date, 
many clinicians still use BPH and LUTS interchangeably 
but it is noteworthy there are important differences 
between the terms. BPH is a histological diagnosis and 
is reserved for the histological pattern it describes, for 
instance, in prostatectomy specimens. Benign prostate 
enlargement (BPE) is used when there is clinical prostate 
enlargement based on the size of the prostate. Neither 
BPE nor BPH can cause LUTS alone in men without 
obstruction. Hence the real cause of LUTS in men in 
the traditional concept of ‘prostatism’ should be benign 
prostatic obstruction (BPO), which is used to denote 
obstruction proven by urodynamic studies (pressure 
flow studies), or highly suspected from uroflowmetry 
or a clinical BPE. BOO is the generic term for all forms 
of obstruction to the bladder outlet (e.g. urethral 
stricture) including BPO. Terms such as ‘BPH patient’, 
‘symptomatic BPH’, ‘clinical BPH’, ‘drugs for BPH’ and 
‘BPH treatment’ are imprecise, cause confusion and are 
therefore not recommended.4 In terms of investigation 
and treatment of LUTS as a result of the prostate, what 
clinicians are interested is not BPH or BPE, but the 
presence or absence of BPO. The common causes for 
LUTS are listed in Table 1. 
Overactive bladder (OAB) is a clinical diagnosis 
defined as urinary urgency with or without urgency 
incontinence, usually with urinary frequency and 
nocturia, in the absence of UTI or other obvious 
pathology. In patients with OAB undergoing pressure 
flow studies, there may or may not be detrusor 
overactivity (DO), defined as involuntary detrusor 
contractions during the filling phase that may be 
spontaneous or provoked.  
Table 1. Common aetiological causes of LUTS in adult men.
Benign prostatic obstruction (BPO)
Overactive bladder (OAB)
Nocturnal polyuria
24-hour polyuria
Detrusor underactivity (DUA)
Neurogenic bladder dysfunction
Urinary tract infection
Prostatitis
Urethral stricture
Bladder tumour
Distal ureteral stone
Basic evaluation
A set of basic evaluations should be offered by all health 
care providers, including primary care physicians to 
every adult man presenting with LUTS. 
History and physical examination
A relevant medical history should be obtained focusing 
on the nature and duration of the voiding symptoms. 
In addition to previous surgical procedures, especially 
those affecting the genitourinary tract, general health 
issues, sexual history and the list of medications the 
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patient is currently taking should be noted. Commonly 
encountered conditions masquerading as LUTS such 
as uncontrolled diabetes, urinary tract infections, 
neurological disorders can be elucidated from a 
careful history. Particular lifestyle factors contributing 
to LUTS such as caffeine or alcohol consumption 
as well as excessive intake of liquids should also be 
noted. Medications such as diuretics, antidepressants 
and those with sympathomimetic or anticholinergic 
properties can have significant effects on an individual’s 
voiding patterns.
A focused physical examination should be performed 
on every patient, classically starting with an overall 
impression of his gait as the patient comes through the 
door. The patient’s overall motor and sensory functions 
with a focus on the perineum and lower limbs should 
be noted. Examination of the abdomen should focus 
on the suprapubic area to rule out bladder distension. 
Digital rectal examination (DRE) should be performed 
on every patient to evaluate the anal sphincter tone 
and the prostate gland, in terms of its approximate 
size, consistency and abnormal nodules suggestive 
of prostate cancer.  However, it should be noted that 
the accuracy of DRE for assessing prostate size varies 
from suboptimal to poor.7,8 Furthermore, the prostate 
size alone does not correlate precisely with symptom 
severity, degree of urodynamic obstruction or treatment 
outcomes.9  On the other hand, the prostate volume 
has been shown to correlate with increased risk of 
disease progression into adverse events such as a rise in 
symptom scores or acute urinary retention. 
Assessment of symptom severity and bother
A semi-quantitative assessment of symptoms and 
bother using a validated questionnaire is strongly 
recommended to grade the severity of the LUTS 
and to understand the degree of bother caused by 
those symptoms. In Hong Kong, the most commonly 
used instrument would be the International Prostate 
Symptom Score (I-PSS), which assesses the frequency 
of three storage symptoms (frequency, nocturia and 
urgency) and four voiding  symptoms (incomplete 
emptying sensation, intermittency, straining and weak 
stream). The I-PSS is usually followed by a bother score 
which evaluates the quality of life of the patient with 
the LUTS (range from 0 = delighted to 6 = terrible). 
Completion of the I-PSS yields a total score ranging 
from 0 to 35 (1-7 for mild symptoms, 8-19 for moderate; 
and 20-35 for severe). However, it should be noted 
I-PSS is just an instrument to rate the severity of LUTS 
but by no means it can aid in the diagnosis of the 
reasons underlying LUTS. The I-PSS has shown a poor 
correlation with underlying BOO and the ability of 
I-PSS in diagnosing BOO is also poor.10-13 A gentleman 
suffering from bothersome LUTS with a high I-PSS score 
could well be having an underlying condition unrelated 
to the prostate, such as bladder cancer. 
Urinalysis and serum prostate-specific antigen 
Urine should be examined using dipstick tests 
to determine if the patient has microhaematuria, 
proteinuria, pyuria or other pathological findings. 
Examination of the urinary sediment and culture is 
indicated if the dipstick is abnormal. Prostate-specific 
antigen (PSA) testing should only take place after 
discussion with the patient about the benefits and 
risks, including the false-positive and false-negative 
results, the possible complications of the subsequent 
confirmatory test, namely prostate biopsy and finally the 
shortcomings of prostate biopsy such as the possibility 
of false-negative biopsy. As recommended by all major 
guidelines, PSA test for the purpose of detection of 
early prostate cancer should only be performed if life 
expectancy is greater than 10 years and if a diagnosis 
of prostate cancer would modify the management 
approach.2-4 On the other hand, serum PSA has been 
shown to be a reasonable predictor of prostate volume 
and risk of disease progression in men with LUTS 
and can be used in this capacity in treatment decision 
making.4 However, we do believe a detailed discussion 
with the patient about the pros and cons of PSA testing 
and the subsequent events following an abnormal result 
is a good practice, given the controversy surrounding its 
use as a tool for prostate cancer screening.14-16 
Serum creatinine
Although measurement of serum creatinine can 
identity patients with renal insufficiency due to BPO 
and these patients have increased risk of postoperative 
complications after BPO surgery, the American Urological 
Association expert Panel, after analysing several large 
LUTS/BPO randomised controlled trials, reported a 
rate of renal insufficiency to be less than 1% and often 
attributed to causes unrelated to the prostate (e.g. 
diabetic nephropathy).17 As a result of the low prevalence 
of renal insufficiency in this group of patients, all major 
guidelines no longer recommend routine assessment of 
serum creatinine in the evaluation process.2-4
 
Frequency volume charts
Frequency volume charts or bladder diaries are 
particularly useful when nocturia is the main dominant 
symptom. In these charts, the time and voided volume 
are recorded for each micturition during several (usually 
three) 24-hour periods. Nocturnal polyuria, defined 
as present when more than 33% of the 24-hour urine 
output occurs at night and 24-hour polyuria, defined 
as total 24-hour urine output more than three litres can 
easily be diagnosed on a bladder diary. In addition, any 
excessive fluid intake, which is common in the elderly, 
can be noted.  
Management after basic evaluation
Referral to urologist for ‘complicated LUTS’
If the basic evaluation demonstrates the presence of 
LUTS associated with one or more of the following 
findings: DRE suspicious of prostate cancer, haematuria, 
abnormal PSA, recurrent infections, palpable bladder 
or neurological disease, the patient should be referred 
to an urologist for further investigation before starting 
treatment. These signs and symptoms are suggestive 
of more serious underlying conditions such as prostate 
cancer or neuropathic bladder. 
Initiation of treatment
On the other hand, when basic evaluation demonstrates 
the presence of bothersome LUTS without the said 
findings, the primary care providers can start treatment 
based on the diagnosis of the underlying causes without 
further tests. Among the conditions causing LUTS, the 
most important are BPO, OAB and nocturnal polyuria. 
It has been suggested that BPO should be objectively 
diagnosed by the use of invasive testing (pressure flow 
urodynamic study) before starting treatment.18 However, 
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nowadays the initiation of non-surgical treatment of 
LUTS and its underlying conditions after a set of basic 
evaluation is universally endorsed by all guidelines.2-4 
This is mainly because it is impractical to subject 
patients to an invasive uncomfortable urodynamic study 
if the management they are offered is simple, safe and 
relatively inexpensive.19 Moreover, even in conditions 
like prostatic obstruction, which were previously 
thought to be potentially dangerous and need early 
treatment, have been shown in longitudinal studies 
to be relatively benign and show little progression.20,21 
Therefore in primary care there should be a discussion 
of the benefits and risks involved with each of the 
recommended treatment options which include lifestyle 
intervention, behavioural modifications and medical 
treatment. The choice of treatment should be reached in 
a shared decision making process between the clinician 
and the patient. 
If the patient is found to have 24-hour polyuria from 
the frequency volume chart and the intake of fluid is 
excessive, he should be educated about appropriate 
intake. In practice, it is suggested that patients with 24-
hour polyuria are advised to aim for an urine output 
of one litre per 24 hours. Similarly, lifestyle changes 
such as reduction of fluid in the evening and avoidance 
of bladder stimulants such as caffeine and alcohol 
should be advised in patients with nocturnal polyuria. 
In refractory cases, desmopressin can be used but it 
is the authors’ opinion that this medication should 
be prescribed by a specialist urologist due to possible 
disturbances to the serum osmolality. 
If the patient’s main complaint is storage symptoms 
and the clinical diagnosis is OAB, then a combination 
of lifestyle modifications (avoidance of bladder 
stimulants), behavioural intervention (bladder training 
and pelvic floor muscle training) and medical treatment 
(antimuscarinics) can be used. Antimuscarinic agents, 
by interrupting the parasympathetic pathway at the 
cholinergic muscarinic receptors, abolish or damp down 
detrusor muscle contractions, thereby relieving the OAB 
symptoms. These agents are contraindicated in patients 
with narrow angle glaucoma and may cause dry mouth 
and constipation. They should be used with caution in 
patients with delayed gastric emptying and history of 
urinary retention.22 There has long been a reluctance to 
use antimuscarinic agents in patients with LUTS due 
to probable BPO as it may exacerbate the underlying 
obstruction and produce urinary retention. Nonetheless, 
studies have shown that antimuscarinics are safe in 
patients with concomitant OAB and urodynamically 
proven BOO with no evidence of adverse effects on 
voiding pressures, residual urine volume or incidence 
of retention.23 In addition, it has now been shown that 
the combination of antimuscarinics to alpha-adrenergic 
receptor blockers (AARB) produces statistically and 
clinically significant improvement in symptoms in 
patients with both storage and voiding LUTS when 
monotherapy with AARB fails.24
If the patients are mainly complaining of emptying 
symptoms and from the basic evaluation there is 
probable BPO, AARB may be used, with or without the 
combination with 5-alpha reductase inhibitors (5ARI). 
It is beyond the scope of this article to discuss the full 
armamentarium of medical treatment to relieve BPO 
but readers are referred to another article in an earlier 
edition for further information.25
Specialised evaluation
After starting basic management, if patients report 
persistent bothersome LUTS, they should be referred to 
urologists for additional specialised evaluation. From 
the results of the specialised evaluation, patients may 
undergo further medical treatment or surgery for their 
underlying conditions.
Uroflowmetry and post-void residual urine  
Objective measurement of variables such as maximum 
urinary flow rate (Qmax) and volume of residual urine 
after voiding gives useful information on micturition and 
can be used to monitor treatment response. However 
it should be noted that a low Qmax rate does not 
distinguish between BPO and detrusor underactivity 
(DUA).26  Studies have shown that using a Qmax of less 
than 10 ml per second, the positive predictive value of 
diagnosing underlying BOO is 70% only but may be 
improved by performing uroflowmetry in a structured 
manner and doing multiple flows.27-29 Moreover, patients 
with obstruction who have high detrusor pressure can 
maintain a normal urinary flow rate.7 It has been shown 
even with a Qmax of over 15 ml per second, 30% of men 
had urodynamically proven BOO.28 Uroflowmetry results 
can also show considerable variations in the Qmax on the 
same or on different days. Because of the intra-individual 
variability and the volume dependency of the Qmax, at 
least 2 flow rates should be obtained, ideally both with a 
voided volume of greater than 150ml. 
Pressure flow studies
Pressure measurement (cystometry) during bladder 
f i l l ing and voiding def ines  several  important 
urodynamic abnormalit ies including BOO and 
overactivity or underactivity of the detrusor muscle. 
As the test is invasive and involves catheterisation, it is 
recommended before invasive therapy such as surgery 
in men, especially in those with Qmax greater than 10 
ml per second. Pressure flow studies are of proven value 
in the evaluation of patients before invasive therapies, or 
when a precise diagnosis of BPO or BOO is important. 
It is currently the only method to distinguish men with 
a low urinary flow rate due to DUA from those with 
BOO. Studies have shown when patients were found 
to have severe LUTS but without BOO, they were less 
likely to benefit from invasive treatment designed to 
relieve outlet obstruction.30 Consequently these patients 
should have their symptoms treated in an appropriate 
fashion by other means. 
Upper urinary tract imaging 
Imaging of the upper urinary tract is not considered a 
routine practice in the workup of patients with LUTS. 
However, it is indicated in patients with one or more 
of the signs/symptoms or history of upper urinary tract 
infection, haematuria, urolithiasis, renal insufficiency 
and recent onset nocturnal enuresis.4 If imaging is 
indicated, an ultrasonography is usually sufficient as the 
initial imaging modality. In addition, certain treatments 
for BPO including medical treatment with 5ARI or open 
surgical prostatectomy require an assessment of the 
prostate size and configuration. This is usually achieved 
with a transrectal ultrasound. However, such imaging is 
not considered necessary in the routine evaluation. 
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Endoscopy of the lower urinary tract
Simi lar  to  ur inary  t rac t  imaging ,  endoscopic 
examination of the lower tract is not indicated routinely 
in the diagnostic evaluation of LUTS. It is however, 
indicated in patients with symptoms of haematuria 
and when certain treatment modalities such as surgical 
transurethral incision of prostate is contemplated.
Conclusions
LUTS is a common presenting symptom among adult 
men and can be bothersome and affects patients’ 
quality of life adversely. Satisfactory management of 
LUTS requires a careful and evidence-based diagnostic 
approach. Primary care physicians should note the 
multifactorial aetiology of LUTS and be able to initiate 
treatment after a set of basic evaluation. Patients should 
be referred to urologists if symptoms are persistently 
bothersome despite basic treatment, invasive therapy 
such as surgery is desired or when ‘red-flag’ features of 
complicated LUTS are present. 
References
1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, 
and treatment of lower urinary tract symptoms in men: focus on the bladder. European 
urology 2006;49:651-8.
2. McVary KT, Roehrborn CG, Avins AL et al. Update on AUA guideline on the management 
of benign prostatic hyperplasia. The Journal of urology 2011;185:1793-803.
3. Oelke M, Bachmann A, Descazeaud A et al. EAU guidelines on the treatment and follow-
up of non-neurogenic male lower urinary tract symptoms including benign prostatic 
obstruction. European urology 2013;64:118-40.
4. Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J. Evaluation and treatment of 
lower urinary tract symptoms in older men. The Journal of urology 2013;189:S93-S101.
5. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ 
1994;308:929-30.
6. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract 
function: report from the Standardisation Sub-committee of the International Continence 
Society. Neurourology and urodynamics 2002;21:167-78.
7. Belal M, Abrams P. Noninvasive methods of diagnosing bladder outlet obstruction in men. 
Part 2: Noninvasive urodynamics and combination of measures. The Journal of urology 
2006;176:29-35.
8. Meyhoff HH, Ingemann L, Nordling J, Hald T. Accuracy in preoperative estimation of 
prostatic size. A comparative evaluation of rectal palpation, intravenous pyelography, 
urethral closure pressure profile recording and cystourethroscopy. Scandinavian journal of 
urology and nephrology 1981;15:45-51.
9. Roehrborn CG, Chinn HK, Fulgham PF, Simpkins KL, Peters PC. The role of transabdominal 
ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy. 
The Journal of urology 1986;135:1190-3.
10. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship 
of symptoms of prostatism to commonly used physiological and anatomical measures of the 
severity of benign prostatic hyperplasia. The Journal of urology 1993;150:351-8.
11. Chancellor MB, Rivas DA, Keeley FX, Lotfi MA, Gomella LG. Similarity of the American 
Urological Association Symptom Index among men with benign prostate hyperplasia (BPH), 
urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction. 
British journal of urology 1994;74:200-3.
12. Ezz el Din K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation between 
uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as 
measured by the International Prostate Symptom Score. Urology 1996;48:393-7.
13. Yalla SV, Sullivan MP, Lecamwasam HS, DuBeau CE, Vickers MA, Cravalho EG. Correlation 
of American Urological Association symptom index with obstructive and nonobstructive 
prostatism. The Journal of urology 1995;153:674-9; discussion 9-80.
14. Brawley OW. Prostate cancer screening: what we know, don't know, and believe. Ann Intern 
Med 2012;157:135-6.
15. Catalona WJ, D'Amico AV, Fitzgibbons WF et al. What the U.S. Preventive Services Task 
Force missed in its prostate cancer screening recommendation. Ann Intern Med 2012;157:137-
8.
16. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force 
recommendation statement. Ann Intern Med 2012;157:120-34.
17. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis 
and treatment recommendations. The Journal of urology 2003;170:530-47.
18. Shah JR. Should we treat lower urinary tract symptoms without a definitive diagnosis? No. 
BMJ 2011;343:d6058.
19. Abrams P. Should we treat lower urinary tract symptoms without a definitive diagnosis? 
Yes. BMJ 2011;343:d6038.
20. Bates TS, Sugiono M, James ED, Stott MA, Pocock RD. Is the conservative management of 
chronic retention in men ever justified? BJU Int 2003;92:581-3.
21. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower 
urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated 
detrusor underactivity. BJU Int 2005;96:1295-300.
22. Gormley EA, Lightner DJ, Burgio KL et al. Diagnosis and treatment of overactive bladder 
(non-neurogenic) in adults: AUA/SUFU guideline. The Journal of urology 2012;188:2455-63.
23. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for 
the treatment of overactive bladder in men with bladder outlet obstruction. The Journal of 
urology 2006;175:999-1004; discussion 
24. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and 
tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: 
a randomized controlled trial. Jama 2006;296:2319-28.
25. Chan SW. Pathology and Medical Management of Benign Prostatic Hyperplasia. Hong Kong 
Medical Diary 2011;16:4-8.
26. Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S. Bladder outlet obstruction versus 
impaired detrusor contractility: the role of outflow. The Journal of urology 1991;145:810-2.
27. Nielsen KK, Nordling J, Hald T. Critical review of the diagnosis of prostatic obstruction. 
Neurourology and urodynamics 1994;13:201-17.
28. Poulsen AL, Schou J, Puggaard L, Torp-Pedersen S, Nordling J. Prostatic enlargement, 
symptomatology and pressure/flow evaluation: interrelations in patients with symptomatic 
BPH. Scandinavian journal of urology and nephrology Supplementum 1994;157:67-73.
29. Reynard JM, Peters TJ, Lim C, Abrams P. The value of multiple free-flow studies in men 
with lower urinary tract symptoms. British journal of urology 1996;77:813-8.
30. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower 
urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome 
after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. 
BJU Int 2004;93:745-50.
Excellence in Endourology
and Lithotripsy
DornierGemini
Distributed by:
Tel: 2648 2822    Fax: 2648 0618
www.tronda.com.hk
Medical Bulletin VOL.19 NO.1 JANUARY 2014
    10
MCHK CME Programme Self-assessment Questions
Please read the article entitled “Diagnostic evaluation of Lower Urinary Tract Symptoms in Men” by Dr James HL 
TSU and Dr Ming-kwong YIU and complete the following self-assessment questions. Participants in the MCHK 
CME Programme will be awarded CME credit under the Programme for returning completed answer sheets via 
fax (2865 0345) or by mail to the Federation Secretariat on or before 31 January 2014. Answers to questions will be 
provided in the next issue of The Hong Kong Medical Diary. 
1. BPH is the only cause contributing to LUTS
2. LUTS may result from diseases of the CNS and peripheral nervous system
3. In patients with overactive bladder, there is always detrusor overactivity noted in pressure flow studies
4. Urinary Tract infections could cause LUTS 
5. Lifestyle factors like caffeine or alcohol consumption, and excessive intake of fluid do not contribute to the 
severity of LUTS
6. The size of the prostate on PR examination correlates precisely with the severity of the LUTS
7. A PSA test should be performed in all patients with LUTS without discussion about the risks and benefits 
of the test
8. All patients with LUTS should have a urodynamic study performed for evaluation purposes
9. Combination of alpha blockers and antimuscarinic drugs could be prescribed for patents with LUTS caused 
by BPH
10. Cystoscopy is still a routine investigation for patients presenting with LUTS caused by BPH
Questions 1-10: Please answer T (true) or F (false) 
ANSWER SHEET FOR JANUARY 2014
Answers to December 2013 Issue
Please return the completed answer sheet to the Federation Secretariat on or before 31 January 2014 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) self-
assessment questions.
Renal Denervation in the Management of Resistant Hypertension
1 4 82 5 93 76 10
1. F T F T F T FF T T4. 8.2. 5. 9.3. 7.6. 10.
Name (block letters):____________________________ HKMA No.: __________________ CDSHK No.: _______________
HKID No.: __ __ - __ __ __ __ X X (X) HKDU No.:  __________________ HKAM No.:  ________________
Contact Tel No.:________________________________ MCHK No.:  __________________ (for reference only)
Diagnostic Evaluation of Lower Urinary Tract Symptoms in Men
Dr James HL TSU
MBBS, FRCS(Urol)
Associate consultant, Division of Urology, Department of Surgery, 
University of Hong Kong Queen Mary Hospital
Dr Ming-kwong YIU
MBBS(HK), FRCS(Ed.), FCSHK, Dip. Urol.(London), FHKAM(Surgery)
Chief and Consultant, Division of Urology, Department of Surgery,
University of Hong Kong, Queen Mary Hospital

Medical Bulletin VOL.19 NO.1 JANUARY 2014
    12
Prof Chi-fai NGDr Ka-lun LO
Urolithiasis
Dr Ka-lun LO
Prof Chi-fai NG
Adjunct Clinical Assistant Professor, Division of Urology, Department of Surgery, CUHK
Associate Consultant, North District Hospital, New Territory East Cluster
Professor, Division of Urology, Department of Surgery, 
The Chinese University of Hong Kong
Introduction
Urolithiasis is a common urological disease and the 
lifetime prevalence is about 10%.1-4 In Hong Kong, due 
to Westernisation of dietary habits and global warming 
effects, the incidence is expected to increase in not only 
adults, but also the paediatric groups. Moreover, the 
recurrent rate for renal stones after treatment is up to 
50%.5-6 Therefore, both effective treatment and preventive 
measures are equally important. 
 
Clinical Presentation
Most of the patients with urinary tract stones are 
asymptomatic. Occasionally, patients may present with 
some dull loin pain or haematuria. However, when the 
stone migrates into the ureter, it may cause obstruction. 
Patients usually present with renal colic, which is severe 
and persistent loin pain, sometimes radiating to the 
groin or even the scrotum. It may also be complicated by 
sepsis, haematuria or renal impairment. Very unusually, 
some patients may present with acute retention of urine 
secondary to urethral stones.
 
Investigation
When a patient is suspected to have urinary stone, plain 
radiography (Kidney-ureter-bladder view, KUB) is the 
first line of investigation. However the pickup rate for 
renal stones is only around 60-70%. This is because of 
the presence of radiolcuent stones and also sometimes 
the stones maybe overlapped by bowel shadows or bone 
structures. 
Ultrasonography (USG) is another important diagnostic 
tool for stones, particularly for radiolucent stones and also 
for the assessment of hydronephrosis in an acute clinical 
condition (Fig 1). It is readily available, reproducible with 
no radiation and contrast usage. However, its drawbacks 
include operator dependancy and also difficulties in 
assessing mid to distal ureteric stones7.
Non-contrast computed tomography (NCCT) has 
replaced intravenous urography (IVU) as a primary 
diagnostic tool in acute renal colics due to its higher 
accuracy8-13. (Fig 2) It can also detect radiolucent stones, 
the stone density and stone-to-skin distance which are 
important parameters to determine the effectiveness of 
extra-corporal shock wave lithotripsy (ESWL). However, 
it carries a higher radiation dose with less information 
about the renal function and urinary collecting system 
anatomy. If NCCT is planned, KUB radiography will not 
be necessary14 .
Apart from imaging, basic laboratory investigations, 
including urine and blood tests are required. Urine 
tests includes urine white cells, red cells, nitrite, 
microscopy and culture. Blood tests include CBC, RFT, 
bone profile, urate and clotting profile if intervention 
is likely or planned. Stone analysis is also required if 
available. For high risk stone formers, more advanced 
metabolic workup including 24 hours urine for 
minerals is required 15.
Fig 1.  Hydronephrosis secondary to an obstructing renal 
stone at the ureteropelvic junction as shown by ultrasound 
examination
Fig 2.  An obstructing ureteric stone as shown in a non-
contrast computerised tomogram
Treatment
As urosepsis due to obstructive stones can be fatal, 
it is very important to rule out and control sepsis. If 
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conservative treatment including fluid resuscitation 
and antibiotics fails, the obstructive system should be 
drained, either in the form of percutaneous nephrostomy 
(PCN) drainage or double-J (JJ) insertion. There are no 
significant differences in terms of the effectiveness and 
complications between these two methods16-20. Definitive 
treatment of stone removal should be delayed till sepsis 
has subsided. 
For pain control of ureteric colics, non-steroidal non-
inflammatory drugs (NSAIDs) have better analgesic 
efficacy with less recurrent pain. It should be the first 
drug of choice if renal function is normal21-24. If the pain 
cannot be controlled medically, urinary drainage either 
in the form of PCN drainage or JJ insertion should be 
considered. 
After ruling out associated urosepsis with adequate pain 
control and renal reserve, observation with periodic 
evaluation of ureteric stones <10mm is an optional 
initial treatment. Medical expulsive therapy using 
alpha-blockers (Tamsulosin) should be considered in 
such patients to facilitate passage of ureteric stones25-28. 
Patients should be followed-up around 4 weeks’ time for 
progress. If the stones show no signs of passage, definite 
treatment, either in the form of ESWL or ureteroscopic 
lithotripsy (URSL) using a rigid ureteroscope or a flexible 
ureteroscope should be considered.   
Renal stones should also be treated in cases of growth, 
obstruction, infection or pain. The treatment of choice 
depends on multiple factors: including stone size, 
position, density, patient’s habitus and etc. ESWL is still 
a primary treatment option for renal stones <20mm. 
With the advancement of optical technology, retrograde 
intrarenal surgery (RIRS) using a flexible ureteroscope is 
increasingly used, particularly previously failed ESWL or 
contraindication to ESWL29-31.
For renal stones >20mm, percutaneous nephrolithotripsy 
(PCNL) is the standard procedure. The standard access 
sheath is between 24-30Fr. Mini-PCNL using an access 
sheath <18Fr or even ultra mini-PCNL (<14Fr) have 
become popular, aiming to lower postoperative pain 
and shorten hospital stay. However, the benefits of mini-
PCNL or ultra mini-PCNL is still controversial.32-33 
Open surgery for urinary tract stones (Fig 3) has become 
a third-line procedure, which accounts for only 1-5% of 
total procedures for urinary stones.34-38 The indication 
is in complex urinary tract stones which are unlikely or 
failed to be cleared by either ESWL or endourological 
procedure. Laparoscopic or even robotic urological 
surgery is increasingly replacing open surgery due to 
advantages of minimally invasive surgery. With the 
advancement of the camera system and endowrist 
technology in robotic systems, it carries advantages in 
suturing and reconstruction like in ureterolithotomy or 
concomitant pyeloplasty39-41. 
 
Prevention
After stone clearance, it is important to give advice 
on dietary and lifestyle modifications to prevent 
stone recurrence. High fluid intake with 2.5-3L/day 
is recommended42. A balanced diet rich in vegetables 
and fibre, normal calcium content, limited protein 
and sodium diet is advised. Adequate exercises and 
avoiding overweight are also important. For high risk 
stone formers, additional prophylaxis, which is usually 
pharmacological treatment is needed according to the 
stone and metabolic analysis. For example, alkaline 
citrate is used in alkalisation of urine, hypocitraturia and 
inhibition of calcium oxalate crystallisation. 
Conclusion
Though stone disease is not a malignant disease, 
untreated ones can be life-threatening. With the 
advancement of lithotripsy technology, it gives a better 
stone clearance rate. However, stone clearance is not the 
end of the story; extra effort is needed to prevent stone 
clearance. 
Fig 3. Open Nephrolithotomy for renal stone
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Introduction
Kidney cancer has the crude incidence of 9.6 /100,000 in 
Hong Kong in 20101. However with the increasing use 
and the advancement of modern imaging modalities, 
more renal masses are diagnosed nowadays, especially 
small renal masses which are <= 4cm in size2,3 (see Figure 
1). With better understanding on the natural history of 
small renal masses and technical advancements, there 
are rapidly emerging modalities of treatment options 
for small renal masses4. Nephron-sparing surgery is the 
main stay of treatment for small renal masses in patients 
who are surgically fit for operation5 contemporarily. 
Figure 1. Right renal mass incidentally detected from CT 
scan.
Figure 2. The specimen photo of clear cell RCC which was 
cut open.
Natural history of small renal masses 
and their presentation
From the retrospective review of 2,935 nephrectomy 
specimens in the Mayo Clinic, renal masses which 
were >=2cm had a chance of malignancy of up to 78%7. 
These renal masses, despite pathologically malignant, 
were usually slow growing. The mean growth rate was 
0.28cm/ year with a mean follow up time of 30 months, 
and the chance of metastasis was 1% only6. On the 
other hand, the lack of growth did not correlate with 
the benign pathology8. Most of the small renal masses 
were found incidentally when the imaging studies are 
performed for other indications9. Incidental detections 
accounted for more than 50% of renal cell carcinoma 
cases, and these tumours were more likely to be organ 
confined and associated with a better prognosis10,11. 
The classic triad of flank pain, gross haematuria and 
a palpable abdominal mass is now uncommon and 
indicates advanced disease10.
Pathology
The most common malignant pathology is renal 
cell carcinoma(RCC), with clear cell RCC being the 
commonest, followed by papillary, chromophobe and 
collecting duct types12 (Figure 2). Sarcomatoid features 
can be present in all histologic subtypes and indicate 
a poor prognosis13,14. Possible benign pathologies are 
angiomyolipoma and oncocytoma12. 
Why nephron-sparing surgery is 
preferred over radical nephrectomy 
for small renal masses?
Although technically it is more challenging in nephron-
sparing surgery when comparing with radical 
nephrectomy, there are clear advantages for choosing 
nephron-sparing surgery, including:
1. Oncological outcome equivalent to radical 
nephrectomy for small renal mass with good 
long-term survival
Studies with data from Mayo Clinic and Memorial 
Sloan Kettering Cancer Center revealed equivalent 
oncological outcomes with radical nephrectomy and 
partial nephrectomy for renal tumour <7cm, in terms 
of recurrence free survival, cancer specific survival and 
overall survival15-17. The 5-year cancer specific survival 
was 95-99%. There was also a randomizsed controlled 
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study from EORTC showed no difference in overall 
survival for patients who had RCC and underwent 
radical nephrectomy or nephron-sparing surgery19. 
A minimal surgical margin clear of malignancy was 
proven to be adequate for equivalent oncological 
outcomes18. 
2. Better preservation of renal function
The 3-year probability of new chronic disease decreased 
from 65% in radical nephrectomy to 20% if nephron-
sparing surgery was chosen20. From the SEER database, 
nephron-sparing surgery was found to have less 
renal morbidity (16% vs 21%) in terms of dialysis, 
dialysis related surgery or renal transplant21. Radical 
nephrectomy, with a greater loss of post-operative renal 
function, had a higher risk of overall mortality (HR 
1.38) and had 1.4 times of cardiovascular events when 
compared with nephron-sparing surgery22. Nephron-
sparing surgery is clearly important in those patients 
with absolute indications (anatomically or functionally 
anephric after radical nephrectomy) and relative 
indications (multiple focal tumours, at high risk of 
recurrence and with background diseases which may 
affect future renal function).
3. Chance of the renal mass to be benign in nature
Though the chance of malignancy is up to 78% for 
size>=2cm contrast enhancing masses found on CT, 
there was~20% chance that these lesions were benign. 
Radical nephrectomy may over-treat these lesions with 
a major loss of renal function for a kidney harbouring 
benign tumour.
4. Complications of nephron-sparing operation was 
not excessively higher than radical nephrectomy
Par t ia l  nephrec tomy,  compared  wi th  rad ica l 
nephrectomy, requires haemostasis of the raw surface 
after resecting the tumour and repairing the collecting 
system. In high volume centres, the risk of post-
operative haemorrhage and urine leakage were 2.1% 
and 1.7% respectively23, which was not excessively 
higher than radical nephrectomy.
Operative approaches
Laparoscopic partial nephrectomy has been more 
popular in these years, with equivalent functional 
outcome, oncological outcome and shorter hospital 
stay when compared with open partial nephrectomy24. 
However it can be associated with an increased risk 
of major urologic complications and longer warm 
ischaemic times. Therefore it has been limited to centres 
with available expertise and careful case selection24. 
Robot-assisted laparoscopic partial nephrectomy has 
emerged in recent years after the launch of the Da 
Vinci System. It is feasible and safe, but its long-term 
outcomes are pending25. The open approach is still the 
preferred approach for complex cases such as tumours 
in the renal hilum, tumuors in a solitary kidney or 
multiple tumours, which has a lower complication rate 
and can achieve a shorter warm ischaemic time26.
Conclusion
Small renal masses are more commonly diagnosed 
nowadays due to the advancement of modern imaging 
modalities. Nephron-sparing surgery for small renal 
masses is the contemporary treatment of choice. In 
selected cases, minimally invasive surgery has an 
emerging role for selected cases, which allows better 
convalescence.
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Haematuria, Its Implications and 
Necessary Investigations
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Introduction
Haematuria is classified into microscopic haematuria 
or gross haematuria according to the presence of 
noticeable red colour in the urine. Gross haematuria 
is the condition of visible blood in urine while 
microscopic haematuria denotes the detection of 
blood in urine only on laboratory test. The definition 
of asymptomatic microscopic haematuria (AMH) 
according to the Americam Urological Association 
(AUA) 2012 guidelines10 is defined as three or more red 
blood cells (RBC) per high powered field (HPF) on a 
properly collected urinary specimen in the absence of an 
obvious benign cause. A positive dipstick for blood in 
the urine indicates either haematuria, haemoglobinuria 
or myoglobinuria and a microscopic examination of the 
centrifuged urine readily establishes the diagnosis. 
Clinical presentation of haematuria
Most microscopic haematuria is not painful or 
noticeable. Most of the time it was detected on urine 
tests either by microscopy or by dipstick test. Gross 
haematuria can appear as obvious bloody urine, or 
sometimes as tea-coloured urine or cloudy urine. Pain 
may or may not be associated with the presence of 
blood.
Differential diagnosis
Haematuria may reflect either significant nephrological 
or urological diseases. It is important to differentiate 
between the two categories as the line of investigations 
for nephrological and urological diseases are very 
different. The hallmarks of nephrological diseases 
causing haematuria include the presence of dysmorphic 
red blood cells, red blood cell casts and proteinuria. 
Haematuria of nephrological origin is frequently 
associated with casts in the urine and almost always 
associated with significant proteinuria. Even significant 
haematuria of urological origins will not elevate the 
protein concentration in the urine into the 100 to 300mg/
dl or 2+ to 3+ range on dipstick, and proteinuria of 
this magnitude almost always indicates glomerular or 
tubulo-interstitial renal disease. 
Urology lesions that can account for haematuria can 
again be categorised into malignant and benign diseases. 
Any malignancies in the urinary tract e.g. bladder cancer, 
upper tract urothelial tumours, renal cancers or prostate 
cancers should be considered as potential reasons for 
the haematuria. Many benign conditions of the urinary 
tract e.g. benign prostatic enlargement in men, urinary 
tract infection, urolithiasis and trauma can also be the 
commoner causes.
Gross haematuria
Gross haematuria is commonly encountered in urology 
practice. It accounts for 13% in a Japanese urologic 
outpatient attendance and 10% of all after-hours 
telephone calls received by residents from outpatients 
and the emergency room.1,2 In particular, when compared 
to microscopic haematuria, it is more alarming in terms 
of its noticeability to the patients as well as the risk of 
more sinister underlying pathologies such as urological 
malignancies, urinary stones or urinary tract infection. 
In fact, some reports about the presence of significant 
urology lesions in  50% patients and urological cancer in 
patients with gross haematuria up to 18 to 24%3,4,5 and 
therefore, early thorough investigation is warranted in 
patients presenting with visible or gross haematuria6,8. 
Urologists like to further categorise the gross haematuria 
into painful or painless haematuria, with the assumption 
that stones and urinary tract infections are usually 
painful, in contrast to malignancies which usually give 
rise to painless haematuria. However, it is also well 
known that urinary stones or even infections can be silent 
and bladder cancers especially carcinomas-in-situ can 
present with serious irritating symptoms like pain and 
frequency as well.
A recent study on a large cohort of patients [n=1804] 
investigated with a standard protocol of urine cytology, 
USG and IVU/ CTU and flexible cystoscopy with a 
median follow up of 6.6 years showed 21.4% patients 
had malignant urological diseases, mostly due to 
bladder tumours [18%] followed by renal tumours [2.2%] 
and less commonly upper tract TCC [0.4%]. Common 
benign lesions accounting for the bleeding included 
large bleeding prostates [13.4%] and UTI & cystitis 
[2%] and urinary tract stones [7.5%]. No pathology was 
found in 53.5% according to this investigation protocol7.
While there is little dispute about the necessity for 
a thorough investigation in patients with gross 
haematuria, there is a paucity of information about 
what to do with the patients with initial negative 
investigations and the subsequent follow ups.  The same 
study reported 11.6% of patients with recurrent gross 
haematuria despite negative initial investigations had 
a malignant pathology and therefore full investigations 
were warranted in patients with recurrent haematuria 
after 1 year.7 
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Microscopic haematuria
With the improvement in health consciousness in 
the general population, more people are receiving an 
urinalysis as a cheap and common screening test in most 
check-up programmes. The detection of microscopic 
haematuria, as defined above is very common even 
among asymptomatic, healthy individuals at 20%9 
Contrary to gross haematuria, the frequency of serious 
urological disease in patients with asymptomatic 
microscopic haematuria is as low as 0.5% to 5%10,11,12. The 
common aetiologies of microscopic haematuria include 
benign prostatic enlargement, infection and calculi. 
Urological malignancies, although not very common 
in this group of patients still have to be excluded. The 
common risk factors for the occurrence of malignancies 
include the male gender, age >35 years, past or current 
smoking, occupational or other exposure to chemicals 
or dyes and analgesics abuse in addition to a history of 
gross haematuria, urologic disorder or disease, chronic 
urinary tract infection, exposure to known carcinogenic 
agents or chemotherapy, such as alkylating agents and a 
chronic indwelling foreign body.10
According to the AUA 2012 guidelines10, asymptomatic 
microhaematuria is defined as three or more RBCs 
per high power filed on a properly collected urinary 
specimen in the absence of an obvious benign cause. A 
positive dipstick does not define AMH, and evaluation 
should be based solely on findings from microscopic 
examination of urinary sediment and not on a dipstick 
reading. A positive dipstick reading merits microscopic 
examination to confirm or refute the diagnosis of AMH. 
Patients who have positive dipstick tests should have 
three additional repeat tests. If at least one of the repeat 
tests is positive on microscopy, then a work-up should 
be undertaken10. However, according to studies,13,14 
a significant proportion of patients with microscopic 
haematuria were not referred for a thorough urological 
examination. The reasons were likely attributed to the 
knowledge that the risk of malignancy in this group 
of patients was not very high and the subsequent 
investigations were costly.
The work-up should begin with a detailed history taking 
and physical examination, renal function estimation 
and to look for evidence suggestive of nephrogenic 
cause of the microscopic haematuria like the findings 
of dysmorphic RBC, proteinuria, cellular casts and or 
renal insufficiency. Should the possible benign causes 
[infection, menstruation, vigorous exercise, medical 
renal disease, viral illness, trauma or recent urological 
procedures] of microscopic haematuria be ruled out 
then a urological evaluation should be initiated10. The 
work-up should include a cystoscopy for patients 
older than 35 years old and for all patients who present 
with risk factors for urinary tract malignancies (e.g. 
irritating voiding symptoms, current or past tobacco use, 
chemical exposures), regardless of age. The AUA also 
recommended investigation of the upper urinary tract 
with a CT Urogram as the imaging procedure of choice10.
In the past, urine cytology and in some centres urine 
markers for bladder cancer (e.g. NMP22, BTA) have been 
part of the urology evaluation protocol for patients with 
microscopic haematuria.  However due to the variable 
specificities and sensitivities of these tests, they are not 
recommended as part of the routine investigations in 
microscopic haematuria patients, and are considered 
only in patients with persistent microscopic haematuria 
with negative work-up or those at risk for carcinoma-
in-situ (i.e. irritating voiding symptoms, current or 
past tobacco use, chemical exposures).10 In view of the 
disappointing performance of the above urine markers, 
there have been newer efforts for development of better 
markers. A recent study identified a panel of microRNAs 
with a high sensitivity for bladder cancer16 and in another 
report a Multi- analyte assay that stratified patients with 
haematuria into high or low risk.17
Despite the AUA recommendations, it is also well 
known that many patients who have undergone the 
full investigations have negative results. A large scale 
recent prospective cohort on 2630 patients detected 
2.1% patients with malignancies and a few risks factors 
were identified to formulate the Haematuria Risk 
Index: age more than 50 years old, male sex, smoking 
history and the degree of microscopic haematuria15. 
Although this index or similar approaches are not 
standard management nowadays, hopefully with more 
information from the researches, the initiation of the 
investigations can be more individualised in the future.
What to do after the initial negative urological 
evaluation is also tricky for many urologists and general 
practitioners. The basic principle is the finding of 
microscopic haematuria with negative initial evaluation 
can represent the absence of urological/ nephrological 
disease, but there exists a possibility that there is an 
urological lesion at its very early developing stage 
that could not be detected by the initial investigations. 
Therefore the AUA recommended yearly urinalysis for 
this group of patients, especially for those who have 
high risk factors for urinary tract malignancies. If the 
annual urinalyses are negative for two consecutive years 
then the patients could be discharged. But repeating the 
evaluation might be necessary within three to five years 
and should be considered for those who are found to 
have persistent microscopic haematuria on the yearly 
follow urinalysis.10
Conclusion
The presence of haematuria, both microscopic and gross 
haematuria often indicates the presence of significant 
urological diseases. There is little dispute that all 
the patients with gross haematuria need thorough 
investigations. The general recommendation for 
microscopic heamaturia is still complete investigation 
for most of the patients. However, hopefully with 
more progress in the knowledge and technology, 
urologists can select out those who are more at risk for 
investigation and spare most of the others to save the 
time and cost for the patients and the society.
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Dermatological Quiz
Dr Lai-yin CHONG
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
Private dermatologist
This middle aged man had mildly pruritic greasy scaly skin rash at the 
face and scalp for six months. The lesions were mainly distributed at both 
nasolabial folds, the nose, gabella and forehead (Fig.1). He was treated by 
a general practitioner with topical combined preparation of hydrocortisone 
and miconazole cream, ketoconazole shampoo and oral loratadine. 
However the skin lesions did not respond to treatment and became worse. 
His past health was good and family history was insignificant.
Questions:
1. What was the preliminary diagnosis of the general practitioner as 
    judged from his treatments?
2. What is the correct diagnosis?
3. How do you differentiate between these two diseases?
4. How do you treat the face and scalp of this patient? 
Fig.1:  Greasy erythematous scaly 
lesions at seborrhoeic area of face
Dr Lai-yin CHONG 
(See P. 32 for answers)
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Erectile Dysfunction: An Under-recognised 
Condition in Hong Kong 
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Introduction
Erectile dysfunction (ED) is defined as the persistent 
inability to attain and maintain an erection sufficient to 
permit satisfactory sexual performance.1 
Higher rates of reporting, diagnosis and treatment 
of  ED have  been  seen  s ince  the  1990s  due  to 
increasing awareness of effective treatment strategies, 
advertisement from pharmaceutical companies 
and awareness of the association between ED and 
cardiovascular diseases (CVD). 
Over the past quarter century, the clinical management 
of erectile dysfunction has changed remarkably, from 
mostly empirical treatments such as psycho-analysis, 
sex therapy and endocrine treatment to the prescription-
only oral PDE5 inhibitors (phosphodiesterase type 5) 
and surgically implanted penile prosthesis.2 
This article aims to give the general practitioner a review 
of the prevalence, aetiology, workup and treatment of 
erectile dysfunction. 
Prevalence
Epidemiological data have shown a high prevalence 
and incidence of ED worldwide. The first large, 
community-based study of ED was the Massachusetts 
Male Aging Study (MMAS)3. The study reported an 
overall prevalence of 52% ED in non-institutionalised 
40-70-year-old men in the Boston area; specific 
prevalence for minimal, moderate, and complete ED 
was 17.2%, 25.2%, and 9.6%, respectively. Another 
population-based study in the United States found the 
age-specific prevalence rates for “trouble maintaining 
or keeping an erection” to be 9%, 11%, and 18% for 
age groups 30-39, 40-49, and 50-59 respectively.4 The 
reported overall prevalence of ED was 36.7% in a 
questionnaire interview of 1506 Hong Kong males of 
age 26 to 70 year old.5
Physiology of erectile response 
Erection is a complex process involving integration of 
psychological, neurological, endocrine, vascular and 
local anatomic systems. Caversonal artery smooth 
muscle relaxation is an active process that is the 
initial event of an erection. Parasympathetic nerves 
release nitric oxide, leading to increased cyclic GMP 
(cGMP), decreased intracellular calcium, and greater 
smooth muscle relaxation. This in turn leads to arterial 
dilatation, increased penile blood flow, increased 
intracaversonal pressure and sinusoid expansion. 
Increased arterial inflow combined with increased 
venous outflow resistance further leads to full erection.6
Aetiology & Risk factors
ED is  cal led the harbinger  of  l i fe- threatening 
cardiovascular events. Studies have shown that more 
than two-thirds of men with hypertension had ED; 
nearly two-thirds of men with ED had dyslipidaemia 
and nearly half of men with ED had a positive stress 
test or significant coronary heart condition. ED was 
also common in diabetes patients.7 Erectile dysfunction 
and coronary artery disease frequently coexist, due to 
underlying endothelial dysfunction, causing blood flow 
restriction.  ED may be a marker for occult coronary 
artery disease (CAD) with a window of opportunity for 
CAD risk reduction of 2 – 5 years. Recognising the link 
between ED and CAD is important for doctors, and may 
improve lives and even save lives. 
Erectile dysfunction shares many common risk factors 
with cardiovascular diseases, including lack of exercise, 
obesity, smoking, hypercholesterolaemia, and metabolic 
syndrome; some of which can be modified.  Even men 
with mild ED have significant cardiac risk factors, thus, 
even men who complain of mild ED should be fully 
evaluated for cardiac risk factors! 
Studies have shown that lifestyle modification and 
pharmacotherapy for cardiovascular risk factors are 
effective in improving sexual function in men with ED. 
In the MMAS, men who began exercising in midlife 
had a 70% reduced risk for ED compared to sedentary 
men and a significantly lower incidence over an 8-year 
follow-up period of regular exercise8. Another study 
of obese men with moderate ED compared 2 years 
of intensive exercise and weight loss with a control 
group given general information about healthy food 
choices and exercise9. Significant improvements in 
body mass index (BMI) and physical activity scores, 
as well as erectile function, were observed in the 
lifestyle intervention group. These changes were highly 
correlated with both weight loss and activity levels. 
The screening of risk factors during the workup of ED 
may allow early recognition of these conditions and 
minimise future cardiovascular complications.
Causes   
The potential aetiology of ED is categorised into 
psychogenic, organic or mixed according to whether 
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there is a presumed psychogenic, endocrinologic, 
neurologic or cardiovascular cause (organic), or a 
coexistence of psychologic or relationship factors 
and organic factors (mixed). It is often quoted that 
80% of ED have organic causes. Many patients have 
a combination of factors.2,6 Psychogenic causes of ED 
usually have sudden onset, situational, with preserved 
morning erection and rigidity. Patients commonly 
have other associated psychological complaints or poor 
relationship with spouse. For organic causes of ED, 
the onset is usual gradual and occurs in all situations. 
Patients usually have chronic medical conditions such 
as diabetes mellitus, hypertension and ischaemic heart 
diseases. There is loss of libido and reduced size of the 
penis can be found. In younger patients, there may be 
history of pelvic trauma or previous pelvic surgery or 
the use of recreational drugs. 
Diagnosis 
Basic work-up 
The cornerstone in the evaluation of ED involves 
a detailed case history, preferably taken from the 
patient and partner, physical examination, and proper 
laboratory tests, in a confidential and non-judgemental 
manner. Extensive diagnostic procedures are generally 
not required to confirm the diagnosis of ED.2,6
The first step in evaluating ED is always a detailed 
medical and sexual history of the patients and 
partners in a relaxed environment.  The sexual 
history should include information about previous 
and current sexual relationships, current emotional 
status, onset and duration of the erectile problem, and 
previous consultations and treatments. The severity 
of ED is classified as mild to severe, according to the 
International Index of Erectile Function11, which is a 
validated psychometric questionnaire to assess different 
sexual function domains.
A complete physical examination with focuses on the 
genitourinary, endocrine, vascular, and neurological 
systems is required. A physical examination may reveal 
unsuspected diagnoses, such as Peyronie’s disease, 
prostatic enlargement or irregularity/nodularity, or 
signs and symptoms suggesting hypogonadism small 
testes, alterations in secondary sexual characteristics. 
Height, weight, waist circumference, blood pressure and 
heart rate should also be measured. 
Laboratory tests for men with sexual problems include 
serum chemistries, fasting glucose, complete blood 
count, lipid profile, and serum total testosterone, with 
the aim to identify and treat any reversible risk factors 
and lifestyle factors that can be modified.
 
Specific diagnostic tests are indicated only in a minority 
of patients with primary erectile disorder. Such patients 
are young patients with a history of pelvic or perineal 
trauma who potentially could benefit from curative 
vascular surgery; patients with penile deformities 
that may require surgical correction e.g. Peyronie's 
disease. Potential medico-legal patients involved 
in sexual abuse, or pre-operatively before penile 
prosthesis implant. Special tests include nocturnal 
penile tumescense, caverject tiral, vascular imaging, 
duplex USG, caversonometry and penile arteriography. 
Detailed discussion of these special tests is beyond the 
scope of this article. 
Treatment
 
A large majority of patients with ED can be managed 
by the primary practitioner. The primary goal in the 
management of a patient with ED is to determine 
its aetiology and treat it when possible. ED may be 
associated with modifiable or reversible risk factors, 
including lifestyle or drug-related factors.2,6,11
First line therapies for ED include lifestyle modification, 
oral PDE5i and the vacuum constriction device. 
Intracaversonal injection is considered second line 
therapy, whereas penile implant is third line therapy.
Taking a complete drug history is important as it is not 
uncommon that a certain medication is an offending 
factor resulting in ED. Anti-hypertensives including 
thiazide diuretics and beta-blockers, and psychiatric 
drugs such as SSRI are common culprits.6 Changing 
to a different dose or type of medication entirely may 
reverse ED in some patients.
Lifestyle modification 
ED is strongly associated with the presence of comorbid 
health conditions such as diabetes, cardiovascular 
diseases, and metabolic syndrome. Optimisation of these 
diseases can improve ED severity and even prevent 
the development of ED. Epidemiologic studies support 
that risk modification may improve erectile function. 
Discontinuation of cigarette smoking results in recovery 
of functional erection status. There is also a beneficial 
role of increasing exercise for ED men with sedentary 
lifestyle12. Obese men with moderate ED and no overt 
symptoms of cardiovascular diseases showed significant 
improvements in IIEF scores after exercise and weight 
control compared with a control group, which followed 
an educational programme alone13.
Oral therapy 
PDE5 inhibitors work by blocking the catalytic action of 
the enzyme that degrades cGMP (6). PDE5i is an effective 
ED treatment and should be offered as first-line treatment 
to patients with ED unless contraindicated11. The U.S. 
Food and Drug Administration (FDA) approved sildenafil 
citrate (Viagra, Pfizer, Inc, New York) in 1998, vardenafil 
hydrochloride (Levitra, Bayer Schering Pharma AG, 
Berlin) and tadalafil (Cialis, Lilly LLC, Indianapolis, IN) 
in 2003. A summary of the 3 commonly used oral PDE5 
drugs is listed in the table below.2 
All three PDE5 inhibitors have demonstrated equivalent 
efficacy and tolerability in clinical trials for the treatment 
of ED of varying severity and cause. In general, 
PDE5i achieve successful sexual intercourse rates of 
approximately 70%. To date, there is no data directly 
comparing the efficacy and/or patient preference for 
sildenafil, tadalafil, and vardenafil. The choice of drug 
will depend on the frequency of intercourse and the 
patient’s personal experience. Patients need to know 
whether a drug is short- or long-acting, its possible 
disadvantages, and how to use it. According to standard 
dosing recommendations, patients are instructed to take 
the medications on demand approximately an hour 
before the intended sexual activity.11
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Contra-indications for PDE5i include the use of nitrates 
in any form (e.g., sublingual nitroglycerin, isosorbide 
dinitrate). Other contraindications include myocardial 
infarction, stroke, or life-threatening arrhythmia 
within the previous 6 months, patients with New 
York Heart Association class II or greater heart failure 
or coronary artery disease causing unstable angina, 
resting hypotension (<90/50 mm Hg) or hypertension 
(>170/100 mm Hg), history of hereditary degenerative 
retinal disorders including retinitis pigmentosa, severe 
hepatic impairment (Child-Pugh C) or end-stage renal 
disease requiring dialysis. Caution is advised when 
PDE5 inhibitors are coadministered with α-adrenergic 
blockers because both agents are vasodilators with 
blood pressure–lowering effects. 
 
It is not uncommon for patients to complain of poor 
efficacy of PDE5i at the clinic. The two main reasons why 
patients fail to respond to a PDE5i are either incorrect 
drug use or lack of efficacy of the drug. There is a large 
black market for PDE5is. The amount of active drug in 
these medications varies enormously and it is important 
to check how and from which source the patient has 
obtained his medication. Moreover, patients may 
not know exactly how to take the medication due to 
inadequate counselling from their physician. The main 
ways in which a drug may be incorrectly used include 
inadequate sexual stimulation; suboptimal dose or failure 
to wait an adequate amount of time between taking the 
medication and attempting sexual intercourse.2 
 
Daily use of PDE5i with once a day (OAD) tadalafil 5 
mg for patients with ED is a relatively new concept, 
with the potential benefit of being able to have more 
spontaneous sexual activity. Non randomised trials 
suggest that daily dosing with a PDE5i might salvage 
some non-responders to intermittent prn dosing.2 A 
recent study comparing the use of Tadalafil OAD 5 
mg with Sildenafil 100 mg showed that efficacy was 
comparable, but that the tadalafil OAD group showed 
improved Sexual Self Confidence, less time concerns 
and more spontaneity.14 Daily dosing of PDE5i appears 
promising. However, more evidence is awaited before 
recommendations on daily dosing can be given. 
Sildenafil (Viagra) Vardenafil (Levitra) Tadalafil (Cialis) 
FDA approval 1998 2003 2003 
Common dose 50 mg / 100 mg 
prn
10 mg / 20 mg prn 10 mg / 20 mg prn 
2.5 mg /5 mg daily 
Peak effect 0.5 – 1 hr 0.7 – 0.9 hr 2 hr 
Half life 2.6-3.7 h 3.9 hr 17.5 hr
Duration of effect 4 hr 4 hr 24 – 36 hr 
Relationship to 
fatty meals 
Yes Yes No
Adverse event Sildenafil (Viagra) Vardenafil (Levitra) Tadalafil  (Cialis)
Headache 12.8% 16% 14.5% 
Flushing 10.4% 12% 4.1%
Dyspepsia 4.6% 4% 12.3%
Nasal congestion 1.1% 10% 4.3%
Dizziness 1.2% 2% 2.3%
Abnormal vision 1.9% <2%
Back pain 6.5%
Myalgia 5.7% 
If drug treatment fails despite the above measures, the 
patients can be offered an alternative therapy such as 
intracavernosal injection therapy or use of a vacuum 
erection device as second line treatment, and penile 
implant as a third line treatment. At this juncture, it 
will be appropriate for specialist referrals.  Similarly, 
specialist referrals may be required for individuals with 
complicated or atypical presentations of ED, including 
younger patients with a history of pelvic or perineal 
trauma; patients with significant penile deformity (e.g. 
Peyronie disease, congenital chordee); complicated 
endocrinopathies (e.g. secondary hypogonadism, 
pituitary adenoma); complicated psychiatric or 
psychosexual disorders (e.g. refractory depression, 
hypoactive sexual desire); presentations requiring 
vascular or neurosurgical intervention(e.g. aortic 
aneurysm, lumbosacral disc disease);  medicolegal 
reasons (e.g. workman’s compensation claims). 
 
Conclusion
Erection is a neuro-vasculo-tissular phenomenon 
under hormonal control.  Erectile dysfunction is 
common worldwide, and shares many risk factors 
with cardiovascular diseases. It is important for the 
general practitioner to recognise ED in the general 
population, and every opportunity should be grasped to 
look for underlying risk factors. Lifestyle modification 
(intensive exercise and decrease in BMI) can improve 
erectile function. Oral PDE5i, unless contraindicated, 
should be offered as a first-line of therapy for erectile 
dysfunction. Those who fail first line treatment for ED 
or with features of primary complicated or atypical 
presentations of ED should be referred to specialists for 
further workup and management. 
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On 17 November 2013, a public talk on ‘Infectious Diseases’ was held at the Federation’s Lecture Hall. As the flu 
season was approaching, the captioned topic was a hot issue in town. The Federation was privileged to organise 
this event with our speaker, Dr Thomas Man-kit SO, president of The Hong Kong Society for Infectious Diseases. 
Dr So delivered the topic on the latest update on H7N9 and other infectious diseases. The participants’ active 
questioning in the Q&A section helped to complete a very successful & interactive seminar. 
The Federation President Cup Soccer Five & Basketball Tournament for 2013 was held at the Ying Wa College on 24 
November and 1 December 2013. This year we were making the third attempt in organising the basketball matches, 
which had proved to make our fraternal activity an even bigger success. There were 23 participating teams in total 
for the Soccer Five and Basketball Tournament, with a record number of participants. 
For the Soccer Five, teams included the Federation Invitation Team, AstraZeneca Hong Kong Limited, 獅子會一
生一世會長球隊 Team 1, Hong Kong Ophthalmological Society, Pfizer Corporation Hong Kong Limited, Jacobson 
Pharma Group, Hong Kong Medical Association, Hong Kong Neurosurgical Society, Bupa (Asia), Hong Kong 
Dental Association and Bayer. 
As for the Basketball Tournament : Hong Kong Medical Supplies, AstraZeneca Hong Kong Limited, 獅子會一生一
世會長球隊 Team 2, Pfizer Corporation Hong Kong Limited, Baxter Healthcare Limited, Jacobson Pharma Group, 
Janssen Pharmaceuticals Company (2 teams), Sanofi-aventis HK Limited, Hong Kong Neurosurgical Society, Hong 
Kong Urological Association and Hong Kong Dental Association.
This year we were honoured to have again the participation of the Sun Hei All Stars Football team (晨曦明星足球隊) 
on the closing day. Our Federation United Team, comprising of members from various teams of the tournament, 
played a friendly exhibition match with the All Star Sun Hei Football team.
We were delighted to have our honourable guests Mr King-shing TANG, GBS, Former Commissioner of Police and 
Mr Man-leung CHOW, President of Sun Hei Sports Club Limited in joining us to present trophies to the winning 
teams.
We would like to congratulate all the winners in the tournaments and express our sincere gratitude to all the 
participants and guests for their active participation and support. We look forward to seeing you again at the 
Federation President Cup Soccer Five & Basketball Tournament in 2014!
The photos were nicely taken and they had already been uploaded onto the Federation’s website 
http://fmshk.org/fmshk.html?id=416
Public Talk - Infectious Diseases
Federation President Cup Soccer Five and Basketball Tournament 2013 
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Champion  : Pfizer Corporation Hong Kong Limited 
1st Runner-Up  : Bupa (Asia) Limited
2nd Runner-Up  : Federation Invitation Team 
Top Scorer  : Mr Jan Lennart LIESKE, Bayer
Champion  : Federation United Team 
1st Runner-Up  : Sun Hei All Star Football Team
Champion  : Jacobson Pharma Group 
1st Runner-Up  : AstraZeneca Hong Kong Limited
2nd Runner-Up  : Pfizer Corporation Hong Kong Limited
Top Scorer  : Mr Sui-lun NG, Jacobson Pharma Group
Federation President Cup Soccer Five and Basketball Tournament 2013 
Exhibition Match 
Basketball Tournament 
Soccer Five Tournament 
The followings were the results of the tournaments: 
    27
VOL.19 NO.1 JANUARY 2014 Federation News
Federation President Cup Soccer Five and Basketball Tournament 2013 
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On 5 December 2013, the Executive Committee members of the Federation of Medical Societies of Hong Kong 
were invited by Audi for its new sports car model launch on board a double-decked vehicular ferry. During the 
celebration party, there were fabulous performances as well as an unveiling ceremony of the sports cars. Our 
Executive Committee members exchanged driving tips and interests with the hosts and spent an enjoyable evening 
together.
The HKFMS Foundation Limited is delighted to continue the support and participation for the annual Central and 
Western Health Festival. This year, the Festival was successfully held on 2-3 November 2013 at the Smithfield Sports 
Centre. In the two-day Festival, over 1,750 citizens joined the Foundation activities. An increased participation 
from our Foundation with 6 health talks and 5 health booths were organised this year, composing of dental checks, 
eye tests, games for older citizens, sensory discrimination tests for children, blood pressure measurements and 
consultations. We would like to express our sincere thanks to the following speakers and member societies, namely 
Dr Ka-kui LEE, Dr Derek SY LI, Dr Tommy CHEUNG, Prof Jihui ZHANG, Ms Sally POON, Mr Nelson LAM, Ms 
Crystal CEN, the Hong Kong Society of Professional Optometrists, Hong Kong Occupational Therapy Association 
and Dr. Sai-kwing CHAN, First Vice-President of the Federation. We would like to also thank the following 
sponsors for their gifts and support: Abbott Medical Optics, Colgate, International Medical, Topcon Beijing (HK) 
Ltd, Alcon Hong Kong Limited, Poon's Pharm (USA) Medicine Limited.
Audi Car-launch Ferry Party
Central & Western District Health Festival 2013/14
Federation News
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The Hong Kong Society of Professional Optometrists
Hong Kong Association for Integration of Chinese-Western Medicine
The Hong Kong Society of Professional Optometrists (HKSPO) was 
established by a group of overseas optometry graduates in 1982. Over 
years of development, we are now having nearly 400 members. Our 
members have undergone university training from either The Hong 
Kong Polytechnic University (PolyU) or optometry school from overseas 
universities. Most members are registered as Part I optometrists under the 
Hong Kong Government Register. 
Since April 1996, all optometrists in HK have to be licensed and registered 
in four different parts under the Register according to their professional 
qualifications or working experience. Part I registered optometrists are 
well-trained in university to examine and diagnose visual problems and 
eye diseases such as glaucoma, cataract and retinal diseases. We prescribe 
corrective lenses and contact lenses as well as provide vision training for 
patients suffering from visual disorders such as amblyopia and strabismus. Part I optometrists will also use ophthalmic 
diagnostic drugs during eye examination. Currently, PolyU is the only university to cultivate optometrists in Hong 
Kong through a five-year bachelor degree programme.
Our society endeavors to promote and improve the science and practice of optometry. We aim at maintaining the highest 
standards of primary eye care services for the public benefits.   In 2012-13, we carried out vision screening activities and 
seminars for hundreds of citizens, as in the Shatin Health Festival 2013, the Central & Western District Health Festival 
and the Elderly EyeCare Day in Wanchai district, in order to enhance the public health awareness. Furthermore, with 
the extension of the Elderly Health Care Voucher Pilot Scheme in 2012, the optometric services are now covered by this 
Government subsidization. This means that the eligible elderly can now use their vouchers to procure primary eye care 
services from the qualified Part I optometrists.
HKSPO celebrated its 30th Anniversary on 22March2013. We are delighted to share the joy with friends in Federation 
for this memorable moment. It was a fruitful and exciting evening filled with Latin Dance and A-cappella performance. 
It was our honour to have Dr Ko Wing Man BBS, JP to be one of our guest speakers. Our society would like to thank for 
his great support to the optometry development.  Also, special thanks to Dr Raymond Lo, President of the FMSHK, for 
attending our anniversary dinner.
Our society will continuously serve the community with our best effort and look forward to collaborating with different 
professions to provide the public all-round healthcare services.  
Hong Kong Association for Integration of Chinese-Western Medicine 
(HKAIM) was incorporated in 2001 with the objective to promote study, 
research and practice of medicine that bring together Traditional Chinese 
and Western medical practitioners, and advance their integration in 
clinical applications and health development.  Our members included 
Doctors, Chinese Medicine Practitioners, Professors, Nurses and Medicine 
Specialists.  Since 2003, we organized scientific activities jointly with the 
Mainland and local medicine communities.  We are both Continuing 
Medicine Education (CME) provider of Chinese Medicine Practitioner and 
Continuing Nursing Education (CNE) provider of Nurse.  Thousands of 
Western Medicine and Chinese Medicine participants have attended our 
Seminars and Conferences. 
Major events during these years:
Cancer Conference: Chinese Medicine and Modern Medicine Approach (15-16 March 2003)
Infectious Disease (Ruibing) Conference: Chinese Medicine and Modern Medicine Management Conference 
(18-19 September 2004)
Cerebrovascular and Cardiovascular Diseases – Integrating Chinese and Western Medicine Conference (4-5 March 2006)
Skin Diseases – Integrating Chinese and Western Medicine Conference (16-17-2007)
Symposium on Global Development in Chinese Medicine (24-25 November 2007)
Acupuncture and Moxibustion in Pain Management Conference 2009 (15-17 May 2009)
Hong Kong International Acupuncture Conference 2011 – Neurological and Mental Illness (14-16 January 2011)
Hong Kong International Integrative Medicine Conference 2012 – Chinese Medicine in Geriatrics (6-8 July 2012)
Recent events in this year:
Certificate Course of Primary Healthcare for Traditional Chinese Medicine Practitioners – 
Community Psychological Medicine (9th December, 2012 – 3rd February, 2013)
Certificate Course of Primary Healthcare for Traditional Chinese Medicine Practitioners – 
Community Paediatrics and Child Health (17th February – 14th April 2013)
Integration Medicine Seminar – Integrative Medicine for Sleep and Mood Disorders: 
from Traditional Empiricism to Clinical Trials (20th April 2013)
Certificate Course of Primary Healthcare for Traditional Chinese Medicine Practitioners – 
Community Geriatrics (28th April – 16th June, 2013)
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MON6
Ms. Tammy HUNG
Tel: 9609 6064
1 CME point
The Management of High Risk Prostate Cancer
Organiser: Hong Kong Urological Association, Chairman: Dr Marco Chan, TMH, Speaker: Dr 
Terence Lai, TMH, Venue: Multi-disciplinary Simulation and Skills Centre, 4/F, Block F, QEH
7:30 pm
Ms. Candy YUEN
Tel: 2527 8285
HKMA Choir Family Concert 2014
Organiser: The Hong Kong Medical Association, Chairman: Dr. CHAN Yee Shing, Venue: 
Theatre, Hong Kong City Hall
8:00 pm
WED8 Dr. Gilberto LEUNGTel: 2255 33681.5 CME points
Hong Kong Neurosurgical Society Monthly Academic Meeting–Shaken Baby Syndrome
Organiser: Hong Kong Neurosurgical Society, Chairman: Dr. KWOK Ngai Fung, Venue: 
Seminar Room, Ground Floor, Block A, Queen Elizabeth Hospital
7:30 pm
SAT11 Ms. Clara TsangTel: 2354 24402 CME pointsHKMA CME - Refresher Course for Health Care Providers 2013/2014Organisers: Hong Kong Medical Association, HK College of Family Physicians & HA-Our Lady of Maryknoll Hospital, Speaker: Mr. Jackie FAN, Venue: Training Room II, 1/F, OPD 
Block, Our Lady of Maryknoll Hospital, 118 Shatin Pass Road, Wong Tai Sin, Kowloon
2:15 pm
SAT18 Miss Nadia HOTel: 2527 82859th HKMA Sports NightOrganiser: The Hong Kong Medical Association, Chairman: Dr. CHAN Hau Ngai and Dr. IP Wing Yuk, Venue: The Grand Hall
7:00 pm
WED22 Miss Hana YEUNGTel: 2527 82851 CME pointHKMA Central, Western & Southern Community Network- Do Patient Characteristics Influence Choice of DPP-4 Inhibitor?Organiser: HKMA Central, Western & Southern Community Network, Chairman: Dr. TSANG 
Chun Au, Speaker: Dr. Norman CHAN, Venue: HKMA Central Premises, Dr. Li Shu Pui 
Professional Education Centre, 2/F., Chinese Club Building, 21-22 Connaught Road Central, 
Hong Kong
1:00 pm
FRI24 Miss Candice TONGTel: 2527 82851 CME pointHKMA Yau Tsim Mong Community Network- Current and Emerging Treatments for AsthmaOrganiser: HKMA Yau Tsim Mong Community Network, Speaker: Dr. LAI Kei Wai, Christopher, Venue: Eaton Smart, Hong Kong (380 Nathan Road, Kowloon)
1:00 pm
Miss Hana YEUNG
Tel: 2527 8285
1 CME point
HKMA Central, Western & Southern Community Network- New Guideline Update in 
Hypertension Management
Organiser: HKMA Central, Western & Southern Community Network, Chairman: Dr. POON 
Man Kay, Speaker: Dr. WONG Bun Lap, Bernard, Venue: HKMA Central Premises, Dr. Li Shu 
Pui Professional Education Centre, 2/F., Chinese Club Building, 21-22 Connaught Road 
Central, Hong Kong
1:00 pm
TUE7 Ms. Nancy CHAN Tel: 2527 8898 FMSHK Officers’ MeetingOrganiser: The Federation of Medical Societies of Hong Kong,  Venue: Gallop, 2/F., Hong Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong 8:00 pm
THU16 Ms. Nancy CHAN Tel: 2527 8898 FMSHK Executive Committee MeetingOrganiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong8:00 pm
TUE21 Miss Hana YEUNGTel: 2527 82851 CME pointHKMA Kowloon West Community Network- Update on Asthma Insights & its ManagementOrganiser: HKMA Kowloon West Community Network, Chairman: Dr. CHAN Ching Pong, Speaker: Dr. CHAN Chung Yan, Anthony, Venue: Crystal Room I-III, 30/F., Panda Hotel, 3 
Tsuen Wah Street, Tsuen Wan, N.T
1:00 pm
THU23 Miss Candice TONGTel: 2527 82851 CME pointHKMA Hong Kong East Community Network- Current and Emerging Treatments for AsthmaOrganiser: HKMA Hong Kong East Community Network, Chairman: Dr. YIP Yuk Pang, Kenneth, Speaker: Dr. LAI Kei Wai, Christopher, Venue: HKMA Head Office (5/F., Duke of 
Windsor Social Service Building, 15 Hennessy Road, Hong Kong)
1:00 pm
Miss Hana YEUNG
Tel: 2527 8285
1 CME point
HKMA Kowloon East Community Network- Practical Aspect in Management of Atopic 
Eczema
Organiser: HKMA Kowloon East Community Network, Chairman: Dr. MA Ping Kwan, Danny, 
Speaker: Dr. CHOW Pok Yu, Venue: East Ocean Seafood Restaurant (??????),Shop 137, 
1/F, Metro City Plaza 3,8 Mau Yip Road, Tseung Kwan O, Kowloon
1:00 pm
Ms. Nancy CHAN 
Tel: 2527 8898 
HKFMS Foundation Committee Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 4/F, 
Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
8:00 pm
THU9 Miss Candice TONGTel: 2527 82851 CME pointHKMA Hong Kong East Community Network- Practical Management of Premature EjaculationOrganiser: HKMA Hong Kong East Community Network, Chairman: Dr. YOUNG Ying Nam, 
Dominc, Speaker: Prof. NG Chi Fai, Venue: HKMA Head Office (5/F., Duke of Windsor Social 
Service Building, 15 Hennessy Road, Hong Kong)
1:00 pm
Miss Hana YEUNG
Tel: 2527 8285
1 CME point
HKMA Kowloon East Community Network- Management of Ischemic Heart Disease in 
Diabetic Patient
Organiser: HKMA Kowloon East Community Network, Chairman: Dr. AU Ka Kui, Gary, 
Speaker: Dr. WONG Ming Ho, Venue: Lei Garden Restaurant (????),Shop no. L5-8, apm, 
Kwun Tong, No. 418 Kwun Tong Road, Kwun Tong, Kowloon
1:00 pm
Ms. Christine WONG
Tel: 2527 8285
HKMA Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. TSE Hung Hing, Venue: 
HKMA Head Office (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong 
Kong)
8:00 pm
FRI3
Date  / Time Function Enquiry / Remarks
Department of Surgery, Hong Kong 
Sanatorium & Hospital
Tel: 2835 8698
1 CME point
Joint Surgical Symposium - Laparoscopic Colorectal Audit
Organisers: Department of Surgery, The University of Hong Kong & Hong Kong Sanatorium & 
Hospital, Chairman: Dr. Angus CHAN, Speakers: Dr. Michael LI & Professor LAW Wai-Lun, 
Venue: Hong Kong Sanatorium & Hospital
8:00 pm
SUN5 Mr. Andie HOTel: 2527 8285RSCP Volleyball TournamentOrganiser: The Hong Kong Medical Association, Chairman: Dr. CHEONG Shao Nean, Venue: Siu Sai Wan Sports Centre6:00 pm
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Answers to Dermatological Quiz
Answers:
1.
2.
3.
4.
Seborrhoeic dermatitis
It is reasonable to make this provisional diagnosis as 
the morphology and distribution of the lesions were 
compatible with it. Seborrhoeic dermatitis typically 
affects the seborrhoeic and intertriginous areas. It has an 
aetiological link with active sebaceous glands, abnormal 
sebum composition and a yeast called Malassezia furfur 
(Pityrosporum ovale). Seborrhoeic dermatitis is a common 
manifestation of HIV infection affecting 70-80% of cases at 
some stage of the disease.
Sebo-psoriasis
The clues of the correct diagnosis in this patient were 
the thick scales, relatively well-demarcated plaques and 
failure to respond to mild topical steroid. Sebo-psoriasis 
is a distinct phenotype of psoriasis, being classified under 
plaque type psoriasis. Psoriasis has genetic predisposition 
with a multifactorial mode of inheritance, which accounts 
for the phenotype heterogeneity. There are now more 
than 7-10 different phenotypes in psoriasis being defined, 
and these different forms may alter their morphology and 
course of disease, switching from one type to another.
Sebo-psoriasis has similarity in morphology and 
anatomical distribution to seborrhoeic dermatitis. 
Sometimes they are indistinguishable from each other as 
both can have greasy yellowish scales, instead of the usual 
dry and silvery scales in psoriasis. It may occur either 
alone or associated with plaque psoriasis elsewhere. In 
general, lesions of sebo-psoriasis are more localised and 
well demarcated at the scalp, with thicker scales, deeper 
red colour, and usually fails to respond to mildly potent 
topical steroids or anti-dandruff shampoo. Lesions of 
seborrhoeic dermatitis are more diffuse at the scalp, with 
fine scales, and usually respond to mildly potent topical 
steroids and antifungals.
Treatments on the face consist of potent topical steroids 
(a new-generation topical steroid is preferred to minimise 
skin atrophy) and topical calcineurin inhibitors. Vit.
D3 analogues and tar are not suitable because of their 
irritating effect on the face. Treatments on the scalp 
include potent topical steroid, calcipotriol and tar in 
gel, lotion or shampoo forms. For thick scaly lesions, 
keratolytic agents (like 2% salicyclic acid, 2% sulphur) 
and emollient (like olive oil) can be added for de-scaling.
Dr Lai-yin CHONG 
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
Private dermatologist
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